EFFICACY OF ITRACONAZOLE IN TREATING AIDS-ASSOCIATED INFECTIONS DUE TO CANDIDA-KRUSEI

被引：9

作者：

COPPOLA, S

ANGARANO, G

MONTAGNA, MT

CONGEDO, P

MONNO, L

BELLISARIO, A

PASTORE, G

机构：

[1] Clinica Malattie Infettive, Universita degli Studi, Policlinico, Bari, I-70124

[2] Institute of Hygiene, University of Bari, Bari

来源：

EUROPEAN JOURNAL OF EPIDEMIOLOGY | 1995年 / 11卷 / 02期

关键词：

CANDIDA KRUSEI; ITRACONAZOLE;

D O I：

10.1007/BF01719497

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Candida krusei is an emerging pathogen, both in HIV negative immunocompromised patients and in HIV seropositive patients. Its onset appears to be due, at least in part, to the use of fluconazole. In HIV positive patients, a long term prophylactic use of fluconazole may select some less pathogenic Candida species, as C. krusei, that may determine persistent oral candidiasis and emerge as systemic pathogen. Itraconazole appears efficacious in treating AIDS-associated C. krusei infections.

引用

页码：243 / 244

页数：2

共 14 条

[1]

Merz W.G., Karp J.E., Schron D., Saral R., Increased incidence of fungemia caused by Candida krusei, J Clin Microbiol, 24, pp. 581-584, (1986)

[2]

McQuillen D.P., Zingman B.S., Meunier F., Levitz S.M., Invasive infections due to Candida krusei: Report of ten cases of fungemia that include three cases of endophthalmitis, Clinical Infectious Diseases, 14, pp. 472-478, (1992)

[3]

Person D.A., Laughlin M., Tanner D., Perfect J., Goorman J.P., Hathorn J.W., Fluconazole and Candida krusei fungemia, N Engl J Med, 325, (1991)

[4]

Wingard J.R., Merz W.G., Rinaldi M.G., Johnson T.R., Farp J.E., Saral R., Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole, N Engl J Med, 325, pp. 1274-1277, (1991)

[5]

Coppola S., Montagna M.T., Angarano G., Congedo P., Bellisario A., Monno L., Bramante L.A., Barbuti S., Pastore G., Onset of Candida krusei and other unusual yeasts in AIDS patients undergoing antifungal prophylaxis with azo-triazolic drugs, Micol Dermat, 7, pp. 141-144, (1993)

[6]

Fisher M.A., Shen S.H., Haddad J., Tarry W.E., Comparison of in vivo activity of fluconazole with that of amphotericin B against Candida tropicalis, Candida glabrata, and Candida krusei, Antimicrob Agents and Chemother, 33, 9, pp. 1443-1446, (1989)

[7]

Galgiani J.N., Susceptibility of Candida albicans and other yeasts to fluconazole: Relation between in vitro and in vivo studies, Rev Infect Dis, 12, pp. S272-S275, (1990)

[8]

Denning D.W., Tucher R.M., Hanson L.H., Stevens D.A., Treatment of invasive aspergillosis with itraconazole, Am J Med, 86, pp. 791-800, (1989)

[9]

Mcllroy M.A., Failure of fluconazole to suppress fungemia in a patient with fever, neutropenia and typhlitis, Journal of Infectious Diseases, 163, pp. 420-421, (1991)

[10]

Barchiesi F., Morbiducci V., Ancarani F., Arzeni A., Scalise G., Trichosporon beigelii fungaemia in an AIDS patient, AIDS, 7, pp. 139-140, (1993)

← 1 2 →